Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according to results of the randomized phase 3 PANORAMA1 trial.

Preclinical studies showed panobinostat (LBH589, Novartis) — an oral pan-deacetylase inhibitor — has anti-myeloma activity when combined with bortezomib (Velcade, Millennium) and dexamethasone.

In the current study, Jesús F. San-Miguel, MD, PhD, head of the department of hematology at the University Hospital of Salamanca in Spain, and colleagues sought to compare bortezomib, dexamethasone and panobinostat with bortezomib, dexamethasone and placebo.

The analysis included 768 patients (median age, 63 years) with relapsed or relapsed/refractory multiple myeloma. About half of patients (48%) had received two or three prior regimens, and 57% had undergone prior autologous stem cell transplant.

Read the complete report on Healio: http://bit.ly/1wjWYoY